Core Viewpoint - The company plans to temporarily use idle raised funds to supplement working capital, ensuring that it does not affect the construction of fundraising projects and normal use of funds [6][11]. Fundraising Basic Situation - The company was approved to issue 60.01 million A-shares at a price of 16.24 yuan per share, raising a total of approximately 974.56 million yuan [1]. - The net amount raised after deducting issuance costs was approximately 879.45 million yuan, with excess funds amounting to approximately 273.77 million yuan [3]. Fundraising Investment Project Basic Situation - The total investment amount for the projects is approximately 605.68 million yuan, all of which is funded by the raised funds [3]. - The company has approved a change in the use of part of the raised funds, allocating 45 million yuan for the "Marketing Network Construction Project" to acquire 60% of the shares in Zhoushan Likang Pharmaceutical Chain Co., Ltd. [4]. Previous Use of Idle Raised Funds - The company previously used 150 million yuan of idle raised funds to supplement working capital, which has been fully returned to the fundraising account within the stipulated period [6][11]. Current Use of Idle Raised Funds - The company plans to use up to 100 million yuan of idle raised funds temporarily to supplement working capital, with a usage period not exceeding 12 months [6][7]. - This use is limited to operations related to the main business and will not be used for stock trading or other non-operational purposes [7]. Necessity and Reasonableness - The decision to use idle funds is aimed at reducing financial costs and supporting the company's operational needs, thereby enhancing its competitiveness in the pharmaceutical health sector [7][9]. Internal Decision-Making Procedures - The board of directors, supervisory board, and independent directors have all approved the use of idle funds, confirming compliance with relevant regulations [8][9][11].
华人健康: 华泰联合证券有限责任公司关于安徽华人健康医药股份有限公司使用闲置募集资金临时补充流动资金的核查意见